Evidence map›Paper›PMID 27090874›Full record

ArticleScientific reports2016

Oncolytic Activity of a Recombinant Measles Virus, Blind to Signaling Lymphocyte Activation Molecule, Against Colorectal Cancer Cells.

Yosuke Amagai, Tomoko Fujiyuki, Misako Yoneda, Koichiro Shoji, Yoichi Furukawa, Hiroki Sato, Chieko Kai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Potential and clinical translation of oncolytic measles viruses.Expert opinion on biological therapy · 2017
    Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yosuke AmagaiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Tomoko FujiyukiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Misako YonedaLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koichiro ShojiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yoichi FurukawaDivision of Clinical Genome Research, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiroki SatoLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Chieko KaiLaboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic virotherapy is a distinctive antitumor therapy based on the cancer-cell-specific infectivity and killing activity of viruses, which exert a considerable antitumor effect with only a few treatments. Because colorectal cancer cells often acquire resistance to the molecular-targeted therapies and alternative treatments are called for, in this study, we evaluated the oncolytic activity against colorectal cancer cells of a recombinant measles virus (rMV-SLAMblind), which is blind to signaling lymphocytic activation molecule (SLAM) and infects target cells via nectin-4/poliovirus receptor-related 4 protein. We examined 10 cell lines including 8 cell lines that were resistant to epidermal-growth-factor-receptor (EGFR) targeted therapy. rMV-SLAMblind infected and lysed the nectin-4-positive cell lines dependently on nectin-4 expression, in spite of mutation in EGFR cascade. Tumour progression in xenograft models was also abrogated by the virus, and the infection of cancer cells in vivo by the virus was demonstrated with both flow cytometry and a histological analysis. Therefore, rMV-SLAMblind is considered a novel therapeutic agent for colorectal cancers, including those resistant to molecular-targeted therapies.

Indexed as

Oncolytic VirusesAnimalsCell Line, TumorChlorocebus aethiopsColorectal NeoplasmsGreen Fluorescent ProteinsHumansInterleukin-1Lymphocyte ActivationMeasles virusOncolytic VirotherapyVero CellsXenograft Model Antitumor AssaysGreen Fluorescent ProteinsInterleukin-1

Identifiers

PMID27090874
PMCPMC4835780
OpenAlexW2340075221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.